title: Pyrrolidine analogues of lobelane: relationship of affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter 2 (VMAT2).
abstract: Ring size reduction of the central piperidine ring of lobelane yielded pyrrolidine analogues that showed marked inconsistencies in their ability to bind to the dihydrotetrabenazine (DTBZ) binding site on the vesicular monoamine transporter-2 (VMAT2) and their ability to inhibit VMAT2 function. The structure-activity relationships indicate that structural modification within the pyrrolidine series resulted in analogues that interact with two different sites, i.e., the DTBZ binding site and an alternative site on VMAT2 to inhibit transporter function.
authors.affiliation: Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 725 Rose Street, Lexington, Kentucky 40536, USA.
authors.forename: Ashish P
authors.initials: AP
authors.lastname: Vartak
authors.forename: Justin R
authors.initials: JR
authors.lastname: Nickell
authors.forename: Jaturaporn
authors.initials: J
authors.lastname: Chagkutip
authors.forename: Linda P
authors.initials: LP
authors.lastname: Dwoskin
authors.forename: Peter A
authors.initials: PA
authors.lastname: Crooks
mesh_terms: D001665:Binding Sites; D008120:Lobeline / Q000031:analogs & derivatives* / Q000737:chemistry; D011485:Protein Binding; D011759:Pyrrolidines / Q000138:chemical synthesis / Q000737:chemistry* / Q000378:metabolism* / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013747:Tetrabenazine / Q000031:analogs & derivatives* / Q000378:metabolism; D050493:Vesicular Monoamine Transport Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000378:metabolism*
chemical_list: D011759:Pyrrolidines; D050493:Vesicular Monoamine Transport Proteins; C540157:lobelane; C032811:dihydrotetrabenazine; D008120:Lobeline; C032519:pyrrolidine; D013747:Tetrabenazine
references.citation: Brain Res. 1994 Dec 19;667(1):118-22
references.pmid: 7534607
references.citation: J Med Chem. 1999 Sep 9;42(18):3726-31
references.pmid: 10479304
references.citation: J Org Chem. 1999 Mar 19;64(6):1979-1985
references.pmid: 11674292
references.citation: Bioorg Med Chem Lett. 2008 Dec 15;18(24):6509-12
references.pmid: 18976906
references.citation: Eur J Pharmacol. 2003 Jul 11;472(3):165-71
references.pmid: 12871750
references.citation: J Med Chem. 2005 Aug 25;48(17):5551-60
references.pmid: 16107155
references.citation: J Pharmacol Exp Ther. 1997 Mar;280(3):1432-44
references.pmid: 9067333
references.citation: Mol Pharmacol. 2007 Dec;72(6):1567-75
references.pmid: 17766642
references.citation: Eur J Pharmacol. 2007 Sep 24;571(1):33-8
references.pmid: 17612524
references.citation: AAPS J. 2006 Nov 10;8(4):E682-92
references.pmid: 17233532
references.citation: Biochem Pharmacol. 2002 Jan 15;63(2):89-98
references.pmid: 11841781
references.citation: Neuropharmacology. 1998;37(1):93-102
references.pmid: 9680262
references.citation: FASEB J. 2000 Dec;14(15):2396-400
references.pmid: 11099457
references.citation: J Clin Psychiatry. 1995 Sep;56(9):395-401
references.pmid: 7665537